Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III non-inferiority trial of preservative-free brinzolamide versus Azopt in open-angle glaucoma or ocular hypertension
2022-002524-12Phase 3Terminated
- Sponsor
- AZAD Pharma AG
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of brinzolamide in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by AZAD Pharma AG. Primary endpoint: Mean diurnal intraocular pressure change at Week 12. Started Jan 2023; status: terminated.
02
Drugs
brinzolamide
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2022-002524-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002524-12.